but very good results in the long run durable stabil desease 22 weeks nsclc 15 weeks sclc patients with ++
and cohort posible till 8 good results also in mesothelioma 66weeks must one of the first cohorts
Results: 16 pts have been treated: median age: 67.5 (48-86), M/F: 7/16. 11 pts have received 50 cycles of EC1456 BIW (median 2; range: 1-16), and 5 pts have received 19 cycles of EC1456 QW (median 4; range: 1-8). The only DLT and treatment related (TR) SAE occurred at 4.5 mg/m2 QW schedule (Grade 3 infusion reaction). There have been no TR-deaths, Grade 4 toxicity, or toxicity causing dose delay, omission or reduction. Most TR-AEs have been Grade 1-2. Stable disease 14 cycles has been observed in 2 pts with FR expression on 99mTc-etarfolatide SPECT scan (mesothelioma; GEJ CA) on BIW schedule, and SD 6 cycles in 1 pt (leiomyosarcoma) on QW schedule. Conclusions: Due to the DLT on the QW schedule, cohort expansion is ongoing at 3.5 mg/m2. Dose escalation of EC1456 BIW is ongoing. EC1456 is generally well tolerated. PK data are anticipated in May 2015. Clinical trial information: 001999738.
in summer 2013 its run to 20 and back to ten with nothing thats all i will said the potence is like tubulysin this can fly to 30 or hold 6 range but i see 20 first than buyout 50-100$ iam here thats safe nothing else